Rohto Pharmaceutical Co Ltd 2025 Integrated Report
Company: Rohto Pharmaceutical Co Ltd
Sector: Manufacturing
Country: Japan
Year: 2025
Type: Integrated Report
Pages: 42
The report describes Rohto's FY2024 growth and sustainability agenda, including the addition of Eu Yan Sang to the Group and expanded healthcare and food-business capabilities. It reports a 46% Scope 1 and 2 reduction target for 2030 compared with fiscal 2013, alongside FY2024 emissions performance. The report also emphasizes Group-wide human-capital development and records 9,144 consolidated employees as of March 31, 2025.
Data Services
From bulk PDFs to structured indicators and machine-readable documents.